<?xml version="1.0" encoding="UTF-8"?>
<p>From September 2011 to April 2013, 50 patients were randomized in a 1:1 fashion to either boceprevir in combination with Peg-IFN/RBV or telaprevir and Peg-IFN/RBV. Of the 50 patients randomized, 3 were lost to follow-up (1 in the boceprevir group, 2 in the telaprevir group). The CONSORT study flow diagram is shown in 
 <xref ref-type="fig" rid="pone.0163945.g001">Fig 1</xref>.
</p>
